Literature DB >> 7656460

Shortening of life span and causes of excess mortality in a population-based series of subjects with rheumatoid arthritis.

R Myllykangas-Luosujärvi1, K Aho, H Kautiainen, H Isomäki.   

Abstract

OBJECTIVES: To obtain information on the shortening of the life span and the causes of excess death in a population-based series of subjects with rheumatoid arthritis (RA).
METHODS: The study included all 1666 subjects who had died in Finland in 1989 and were entitled under the nationwide sickness insurance scheme to receive specially reimbursed medication for RA. Demographic data on the Finnish population and sickness insurance statistics were used as the basis for computations.
RESULTS: The life span in subjects with RA was shortened by 15-20% from the date of onset of illness. The determinants of excess mortality could be studied in females. About 40% of the excess deaths were due to cardiovascular causes, 30% to infections, 15% to amyloidosis, and the remaining 15% to diverse causes.
CONCLUSION: This data provides an enlightened basis for understanding mortality associated with RA.

Entities:  

Mesh:

Year:  1995        PMID: 7656460

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  25 in total

1.  Improvement in 5-year mortality in incident rheumatoid arthritis compared with the general population-closing the mortality gap.

Authors:  Diane Lacaille; J Antonio Avina-Zubieta; Eric C Sayre; Michal Abrahamowicz
Journal:  Ann Rheum Dis       Date:  2016-12-28       Impact factor: 19.103

2.  Assessing immune function by profiling cytokine release from stimulated blood leukocytes and the risk of infection in rheumatoid arthritis.

Authors:  Megan L Krause; John M Davis; Keith L Knutson; Michael A Strausbauch; Michael A Strausbach; Cynthia S Crowson; Terry M Therneau; Peter J Wettstein; Eric L Matteson; Sherine E Gabriel
Journal:  Clin Immunol       Date:  2011-05-30       Impact factor: 3.969

Review 3.  Mechanisms of premature atherosclerosis in rheumatoid arthritis and lupus.

Authors:  J Michelle Kahlenberg; Mariana J Kaplan
Journal:  Annu Rev Med       Date:  2012-09-27       Impact factor: 13.739

4.  Incidence of rheumatoid arthritis in Finland during 1980-1990.

Authors:  O Kaipiainen-Seppänen; K Aho; H Isomäki; M Laakso
Journal:  Ann Rheum Dis       Date:  1996-09       Impact factor: 19.103

5.  Capability for daily activities in old people with rheumatoid arthritis: a population based study.

Authors:  M Kauppi; S Hartikainen; H Kautiainen; K Laiho; R Sulkava
Journal:  Ann Rheum Dis       Date:  2005-01       Impact factor: 19.103

6.  Autoantibodies binding to citrullinated telopeptide of type II collagen and to cyclic citrullinated peptides predict synergistically the development of seropositive rheumatoid arthritis.

Authors:  Marja-Kaisa Koivula; Markku Heliövaara; Jarmo Ramberg; Paul Knekt; Harri Rissanen; Timo Palosuo; Juha Risteli
Journal:  Ann Rheum Dis       Date:  2007-05-01       Impact factor: 19.103

7.  Mortality in patients with rheumatoid arthritis treated actively from the time of diagnosis.

Authors:  R Peltomaa; L Paimela; H Kautiainen; M Leirisalo-Repo
Journal:  Ann Rheum Dis       Date:  2002-10       Impact factor: 19.103

8.  Vaccination response to protein and carbohydrate antigens in patients with rheumatoid arthritis after rituximab treatment.

Authors:  Maria Rehnberg; Mikael Brisslert; Sylvie Amu; Kiandoht Zendjanchi; Gunilla Håwi; Maria I Bokarewa
Journal:  Arthritis Res Ther       Date:  2010-06-08       Impact factor: 5.156

9.  Ventricular function abnormalities in active rheumatoid arthritis: a Doppler echocardiographic study.

Authors:  Funda Levendoglu; Ahmet Temizhan; Hatice Ugurlu; Ayse Ozdemir; Mehmet Yazici
Journal:  Rheumatol Int       Date:  2003-06-19       Impact factor: 2.631

Review 10.  Epidemiology and burden of illness of rheumatoid arthritis.

Authors:  Tore K Kvien
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.